A methodological framework for assessing the benefit of SARS-CoV-2 vaccination following previous infection : case study of five- to eleven-year-olds

[thumbnail of WRAP-methodological-framework-assessing-benefit-SARS-CoV-2-vaccination-following-previous-infection-Wilde-2023.pdf]
Preview
PDF
WRAP-methodological-framework-assessing-benefit-SARS-CoV-2-vaccination-following-previous-infection-Wilde-2023.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1MB) | Preview

Request Changes to record.

Abstract

Vaccination rates against SARS-CoV-2 in children aged five to eleven years remain low in many countries. The current benefit of vaccination in this age group has been questioned given that the large majority of children have now experienced at least one SARS-CoV-2 infection. However, protection from infection, vaccination or both wanes over time. National decisions on offering vaccines to this age group have tended to be made without considering time since infection. There is an urgent need to evaluate the additional benefits of vaccination in previously infected children and under what circumstances those benefits accrue. We present a novel methodological framework for estimating the potential benefits of COVID-19 vaccination in previously infected children aged five to eleven, accounting for waning. We apply this framework to the UK context and for two adverse outcomes: hospitalisation related to SARS-CoV-2 infection and Long Covid. We show that the most important drivers of benefit are: the degree of protection provided by previous infection; the protection provided by vaccination; the time since previous infection; and future attack rates. Vaccination can be very beneficial for previously infected children if future attack rates are high and several months have elapsed since the previous major wave in this group. Benefits are generally larger for Long Covid than hospitalisation, because Long Covid is both more common than hospitalisation and previous infection offers less protection against it. Our framework provides a structure for policy makers to explore the additional benefit of vaccination across a range of adverse outcomes and different parameter assumptions. It can be easily updated as new evidence emerges.

Item Type: Journal Article
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RJ Pediatrics
Divisions: Faculty of Science, Engineering and Medicine > Science > Statistics
SWORD Depositor: Library Publications Router
Library of Congress Subject Headings (LCSH): COVID-19 (Disease) , COVID-19 (Disease) -- Vaccination, Vaccination of children -- Mathematical models
Journal or Publication Title: Vaccines
Publisher: MDPI
ISSN: 2076-393X
Official Date: 16 May 2023
Dates:
Date
Event
16 May 2023
Published
11 May 2023
Accepted
Volume: 11
Number: 5
Article Number: 988
DOI: 10.3390/vaccines11050988
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons open licence)
Date of first compliant deposit: 25 July 2023
Date of first compliant Open Access: 26 July 2023
RIOXX Funder/Project Grant:
Project/Grant ID
RIOXX Funder Name
Funder ID
SP/19/3/34678
British Heart Foundation
UNSPECIFIED
Health Data Research UK
UNSPECIFIED
MC_PC_20058
UK Research and Innovation
Feuer International Scholarship in Artificial Intelligence
University of Warwick
EP/S021612/1
UK Research and Innovation
Clinical Top-Up
[MRC] Medical Research Council
UNSPECIFIED
University College London Hospitals NHS Foundation Trust
UNSPECIFIED
Great Ormond Street Hospital for Children
URI: https://wrap.warwick.ac.uk/176021/

Export / Share Citation


Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item